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Atrial natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) exert their physiological actions by binding to natriuretic
peptide receptor A (NPRA), a receptor guanylate cyclase (rGC)
that synthesizes cGMP in response to both ligands. The family of
rGCs is rapidly expanding, and it is plausible that there might be
additional, as yet undiscovered, rGCs whose function is to
provide alternative signalling pathways for one or both of these
peptides, particularly given the low affinity of NPRA for BNP.
We have investigated this hypothesis, using a genetically modified
(knockout) mouse in which the gene encoding NPRA has been
disrupted. Enzyme assays and NPRA-specific Western blots
performed on tissues from wild-type mice demonstrate that
ANP-activated cGMP synthesis provides a good index of NPRA
INTRODUCTION
Natriuretic peptides (NPs) reduce blood pressure through inte-
grated actions on a number of target organs [1–4]. Mice carrying
mutations that disrupt the genes encoding atrial NP (ANP) or its
receptor, NP receptor A [NPRA, also called guanylate cyclase
(GC)-A], have higher than normal blood pressures and sub-
sequent cardiovascular disease [5–7]. Mice that overexpress ANP
or NPRA have, by contrast, lower than normal blood pressures
[5,8,9]. This suggests that genetic polymorphisms in pathways
that mediate NP signalling may contribute to hereditary hy-
pertension, a disease that puts millions of humans at risk for
stroke, heart disease and kidney failure.
The NP family includes three structurally related molecules.
ANP, the first identified member of the family, is produced
primarily by atrial myocytes, where it is stored in granules and
released when the myocytes are subjected to mechanical stretch
[2]. Once in the circulation, ANP triggers a variety of mechanisms
that reduce blood pressure. For example, it induces natriuretic
and diuretic responses in the kidney, reduces total peripheral
resistance, inhibits the activity of the renin–angiotensin–
aldosterone system, and suppresses the output of the sympathetic
nervous system [2,3]. These ANP-activated responses are pri-
marily mediated by NPRA [1], a receptor GC (rGC) that
synthesizes cGMP when exposed to ANP [10,11]. The elevated
cGMP in turn activates downstream effectors, such as cGMP-
dependent protein kinases [12], cGMP-gated channels [13] and
cGMP-sensitive phosphodiesterases [14], in order to bring about
the physiological responses.
The second member of the NP family, B-type NP (BNP), was
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protein expression, which ranges from maximal in adrenal gland,
lung, kidney, and testis to minimal in heart and colon. In
contrast, immunoreactive NPRA is not detectable in tissues
isolated from NPRA knockout animals and ANP- and BNP-
stimulatable GC activities are markedly reduced in all mutant
tissues. However, testis and adrenal gland retain statistically
significant, high-affinity responses to BNP. This residual response
to BNP cannot be accounted for by natriuretic peptide receptor
B, or any other known mammalian rGC, suggesting the presence
of a novel receptor in these tissues that prefers BNP over ANP.
Key words: adrenal gland, brain natriuretic peptide receptor, C-
type natriuretic peptide, guanylate cyclase, testis.
first detected in extracts of porcine brain [15], but was subse-
quently shown, like ANP, to be expressed primarily in the myo-
cardium [16]. Also like ANP, BNP is released into the
circulation when the heart is stretched [17], and its known
physiological effects on target organs are similar to those of
ANP. However, in contrast to ANP, which is almost exclusively
found in atria, a significant amount of BNP is present in
ventricular myocytes [18], suggesting that in some circumstances
the two peptides might play distinct physiological roles.
A third NP, C-type NP (CNP), is expressed primarily in non-
cardiac tissues [19] and is found only at low or undetectable
levels in plasma [20,21]. Its actions are thought to be paracrine
rather than endocrine in nature [4]. CNP also differs from ANP
and BNP in that it has little intrinsic natriuretic activity [22],
though it does play an important role in cardiovascular physi-
ology as a potent vasorelaxant [4], as well as an inhibitor of
vascular smooth muscle proliferation [23] and endothelial cell
migration [24].
As might be expected from its distinct spectrum of physio-
logical actions, CNP does not act through NPRA, the receptor
that mediates the effects of ANP. Instead, CNP selectively
activates NP receptor B [NPRB (also referred to as GC-B)], a
second rGC that is related to NPRA, but only weakly sensitive
to ANP and BNP [25]. Surprisingly, the identity of the receptor
that mediates the effects of BNP is not well established. BNP can
activate NPRA, though its potency is about 10-fold lower than
that of ANP [26,27], and at least some of the physiological
actions of BNP have been shown to depend on the presence of
functional NPRA [28]. However, the relatively low affinity of
NPRA for BNP has led to speculation that an additional BNP-
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specific rGC remains to be discovered [29]. Indeed, the rapid
growth of the rGC family in recent years [30] leaves open the
possibility that there might be additional rGCs that mediate
responses to ANP as well, analogous to the multi-component
receptor families that are targeted by other hormones and
neurotransmitters.
It is difficult to establish the existence of additional BNP- or
ANP-sensitive rGCs against the background of prominent
NPRA expression present in a normal animal. However, gene
targeting has recently been used to produce knockout mice
completely lacking NPRA [7,31], providing an ideal system in
which to examine this possibility. In the present study we show
that NPRA-associated immunoreactivity and NPRA-associated
enzyme activity can be detected in a variety of wild-type
tissues, whereas in knockout animals immunoreactive NPRA
can no longer be detected and responses to both ANP and BNP
are greatly attenuated. However, Npr1−/− (Npr1 is the gene
encoding NPRA in mice) animals retain a statistically significant
level of residual, BNP-preferring enzyme activity in testis and
adrenal gland, suggesting the presence of a novel, BNP-selective
receptor in these tissues.
EXPERIMENTAL
Mouse genotype analysis
The wild-type (Npr1+/+) and knockout (Npr1−/−) mice used in this
study were of a mixed 129}C57BL6 genetic background derived
from the original mutants reported previously [7]. Animals were
genotyped by multiplex PCR using: primer A (5«-GCTCT-
CTTGTCGCCGAATCT-3«), a sequence 5« to the mouse Npr1
gene common to both alleles ; primer B (5«-TTTAGAGCA-
GGTGAGAGCGA-3«), an exon 1 sequence only present in the
intact mouse allele ; and primer C (5«-GCTTCCTCGTGCT-
TTACGGT-3«), a sequence in the neomycin resistance cassette
only present in the null allele. The PCR reaction from tail DNA
included 50 mM Tris, 20 mM ammonium sulphate, 1.5 mM
MgCl
#
, 10% DMSO, 100 µM of each dNTP, 2 units of Taq
polymerase and 40 nM primers. The PCR cycling conditions
were 30 s at 94 °C, 30 s at 60 °C and 1 min at 72 °C for 35 cycles.
PCR products were resolved on a 2% agarose gel. Amplified
products corresponding to the wild-type and targeted alleles were
330 bp and 250 bp respectively.
GC assays
Adrenal gland, lung, kidney, testis, liver, colon, forebrain, heart,
and thoracic aorta were removed from 2–6-month-old mice
euthanized by anaesthetic overdose with avertin or urethane. For
adrenal gland and aorta, tissues were pooled from multiple
animals in order to obtain sufficient material. After dissection,
tissues were rinsed with Buffer B (50 mM Hepes, 1 mM EDTA
and 0.01% bacitracin) and homogenized in ice cold Buffer B
(1 ml}0.5 g of tissue weight) using a motor-driven Potter–
Elvehjem homogenizer with a glass pestle. After an initial
centrifugation at 800 g for 5 min at 4 °C to remove tissue
fragments, the supernatant fraction was centrifuged at 100000 g
for 1 h at 4 °C in a Ti-50 rotor (Beckman Instruments). The high
speed supernatant fraction was then discarded, and the pellet
was resuspended by homogenizing in ice cold Buffer B (1 ml}0.5 g
of original tissue weight), diluted 8-fold with Buffer B, and stored
on ice until assayed for activity, usually within 15 min. Protein
content was determined on a portion of the diluted membranes
(solubilized in 1 M NaOH) using a dye-binding assay (Bradford
assay, BioRad).
To initiate cyclase activity, a portion of the diluted membranes
was incubated with an equal volume of Buffer A [50 mM Hepes,
8 mM MgCl
#
, 2 mM 3-isobutyl-1-methylxanthine (IBMX),
4 mM ATP, 4 mM GTP, 60 mM phosphocreatine, 800 µg}ml
creatine phosphokinase (185 units}mg) and 1 mg}ml BSA] at
37 °C, with or without ANP-28, BNP-45, or CNP-22 [all peptides
were the rat or mouse form (Peninsula or Phoenix Pharma-
ceuticals)]. At various times thereafter, 40 µl samples were
pipetted from this incubation mixture into 100 µl of 6% (w}v)
trichloroacetic acid. Each sample was then extracted four times
with 3 volumes of diethyl ether, to remove trichloroacetic acid,
and the cGMP content was determined by radio-immunoassay.
Results are expressed as pmol of cGMP synthesized}mg of
protein per min, as determined by linear regression analysis of 0,
5 and 10 min time points. Basal and ligand-stimulated rates of
cGMP synthesis are always measured in parallel for each
membrane preparation. Net ligand-stimulated cGMP synthesis
is represented by the difference between these two rates. To avoid
problems that could arise due to sequestration of ligands by
NPRC (a clearance receptor that binds all known NPs with high
capacity), we typically used ANP, BNP and CNP at 0.1 or 1 µM.
This is well above the concentrations required to saturate NPRC,
which range from 0.01–1 nM, depending on the ligand, the
source of receptor and the assay conditions [32].
Every individual determination represents results obtained
from an independent animal. To eliminate assay-to-assay varia-
bility, the elements of each data set were always analysed in a
single immuno-assay. To facilitate interassay comparisons, all
data sets have been normalized so that the basal rates of cGMP
synthesis measured in lung membranes are distributed about a
common mean value (chosen arbitrarily as the basal rate obtained
from our largest data set). Statistically significant differences
between treatment groups (P! 0.05) were confirmed using either
an unpaired or, where appropriate, a paired two-tailed t-test
(Microsoft Excel). For concentration–response curves (see
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Organs were obtained as above, and homogenized with a poly-
tron (Brinkmann, Westbury, NY, U.S.A.) in ice-cold buffer
C [20 mM Tris(hydroxymethyl)-2-aminoethanesulphonic acid,
10 mM mannitol, pH 7.4, 30 µg}ml PMSF, 2 µg}ml leupeptin
and 16 µg}ml benzamidine]. Membrane and cytoplasmic frac-
tions were separated by centrifugation, as described above, and
membranes were resuspended in buffer C containing 1% (v}v)
Triton X-100, then re-centrifuged to yield Triton X-100-soluble
and -insoluble fractions. Protein concentrations were measured
using the bicinchoninic acid protein assay reagent (Pierce).
Protein (60 µg) in the Triton X-100-soluble fraction was
electrophoresed on SDS}PAGE (7.5% gels), transferred to
Immobilon-P and analysed by chemiluminescent Western blot-
ting as described previously [7] using antiserum 281. This
antibody is directed against the rat NPRA extracellular domain,
and was generated by immunizing rabbits with recombinant
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polyhistidine-tagged NPRA [residues 242–493] purified after
bacterial expression (P. J. Mohler and S. L. Milgram, unpub-
lished work). Immunoreactive bands corresponding to NPRA
are found only in the Triton X-100-soluble fraction.
RESULTS
Evaluation of NPRA expression by Western blotting
We performed immunoblots with an NPRA-specific polyclonal
antibody as an activity-independent way to assess the relative
abundance of NPRA in various tissues. In Npr1+/+ tissues,
NPRA typically appears as a broad heterogeneous zone of
immunoreactivity whose apparent molecular mass (spanning
130–135 kDa, marked by the arrow in Figure 1a) agrees with
previous estimates [10,33]. A tissue comparison (Figure 1b)
Figure 1 Immunoblot analysis of NPRA expression
Western blots were performed on tissue extracts from wild-type (­/­) or NPRA knockout
(®/®) mice, as indicated, using a polyclonal antibody raised against an isoform-specific
region of the extracellular domain of rat NPRA. Each lane of a 7.5% PAGE was loaded with
60 µg of membrane protein. (a) A full-length immunoblot shows a broad band of
immunoreactivity in the 130–135 kDa range (marked by the arrow) which, based on size and
genotype-dependent expression levels, corresponds to NPRA. (b) Relevant regions (130–
135 kDa) taken from immunoblots performed on the indicated panel of tissues. Adjacent lanes
were loaded with equivalent amounts of protein extracted from Npr1+/+ and Npr1−/−
membranes. (c) Comparison of NPRA from lung and kidney on a gel that fortuitously displayed
exceptional resolution, revealing differential processing of NPRA in the two tissues.
Figure 2 Characterization of the GC assay
(a) A time course of cGMP synthesis was established for Npr1+/+ kidney membranes in the
presence (E) or absence (D) of 1 µM ANP over a 30-min period. Each symbol represents
the mean value determined for membrane samples from two independent animals, each assayed
in duplicate. Error bars indicate the range defined by the two animals. (b) Cyclase activity is
proportional to the amount of membranes included in the assay. Each point indicates the initial
rate of cGMP synthesis (i.e. the slope of a line fit by linear regression to duplicate 0, 5 and
10 min time points) in the presence (E) or absence (D) of 1 µM ANP, plotted as a function
of the protein concentration of the extract. Results are representative of four similar experiments.
In all cases, cyclase activity was linear over the range of protein concentrations used in our
studies.
reveals that the specific activity of this immunoreactive material
is high in Npr1+/+ lung, kidney, adrenal gland, liver and testis,
while expression is below the limit of detection in Npr1+/+
colon, brain, heart and aorta. No NPRA-associated immuno-
reactivity is observed in any Npr1−/− tissue.
The complex and somewhat variable appearance of the NPRA
band is likely due to the presence of alternatively processed
subspecies with different degrees of N-linked glycosylation, as
has been demonstrated previously in cell lines that overexpress
recombinant NPRA [34,35]. Our results suggest that processing
of native NPRA in io may occur in a tissue-specific manner. In
adjacent lanes on gels with fortuitously high resolution, NPRA
from Npr1+/+ kidney migrates as a distinct single band of
approx. 135 kDa, whereas NPRA from Npr1+/+ lung migrates
as a doublet of approx. 130 and 135 kDa (Figure 1c).
Evaluation of NPRA and NPRB expression by enzymic assay
We have used a quantitative cyclase assay to evaluate rGC-
associated enzyme activity. The assay measures the rate at which
cGMP is synthesized by isolated membranes in the presence and
absence of ligand under standard optimized conditions. Our
initial studies investigated the linearity of the cyclase assay with
respect to time and protein concentration. The time course of
basal and ANP-activated cGMP synthesis is illustrated in Figure
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Figure 3 Sensitivity of lung membranes to ANP, BNP and CNP
Concentration–response analysis of the effects of ligands on lung membranes from Npr1−/− (D) or Npr1+/+ (E) animals. All results are reported as fold-stimulation (stimulated rate/basal
rate). The results for Npr1−/− animals have been adjusted to reflect the fact that the basal rate in Npr1−/− lung is 79% of the basal rate in Npr1+/+ lung (see Figure 9). In (a) each point
provides the mean value determined for two independent animals, and the error bars indicate the range. In (b) each Npr1+/+ point reports the mean³S.E.M. (n ¯ 4), whereas each Npr1−/−
point provides the mean³range (n ¯ 2). For (c), each point gives the mean³S.E.M. (n ¯ 3). Solid lines were calculated using either a one- or a two-site model, as described in the Experimental
section. The EC50 used to calculate the Npr1+
/+ ANP responses was 5 nM; Vmax for Npr1+
/+ ANP responses was 7.6 ; EC50 for Npr1+
/+ BNP responses was 2 nM; Vmax for Npr1+
/+ BNP
responses was 7.0 ; EC50(low affinity) for Npr1+
/+ CNP responses was 0.6 µM; Vmax(low affinity) for Npr1+
/+ CNP responses was 4.3 ; EC50(high affinity) for Npr1+
/+ CNP responses was 0.6 nM;
Vmax(high affinity) for Npr1+
/+ CNP responses was 1 ; EC50(high affinity) for Npr1−
/− CNP responses was 0.6 nM; and Vmax(high affinity) for Npr1−
/− CNP responses was 0.9.
2(a) for Npr1+/+ kidney membranes. In the absence of agonist the
reaction is linear over 30 min, while in the presence of agonist
the rate is approximately linear over the first 10 min and declines
to near zero by 30 min. Non-linear reaction kinetics have been
observed previously for agonist-activated NPRA, and are
thought to reflect receptor desensitization [36]. Despite this
inactivation process, the initial linear rate of cGMP synthesis in
the presence of agonist can be quantified by regression analysis
of 0, 5 and 10 minute time points. For the time course shown in
Figure 2a, the initial rate under basal conditions is 2.4 pmol}min
per mg of protein, while in the presence of ANP it is 34 pmol}
min per mg of protein (nearly a 14-fold increase).
The assay is also linear over a wide range of input activity
(Figure 2b), and the constant ratio between stimulated and
control rates indicates that the cyclase assay should accurately
reflect relative enzyme levels despite differences in protein yield
from preparation to preparation. We routinely use protein
concentrations of 1.25 µg}µl or less, well within the lower end of
the range of concentrations tested here.
We then used membranes from lung, a tissue that expresses
relatively high levels of both NPRA and NPRB mRNA [26,37],
to characterize the properties of the murine forms of these rGCs
in a native setting. As shown in Figure 3(a), the EC
&!
for ANP in
Npr1+/+ membranes is approx. 5 nM, in good agreement with
previous reports [26,27]. In contrast, Npr1−/− membranes are
quite insensitive to ANP, even at the highest concentration
tested. The EC
&!
for BNP in Npr1+/+ membranes is 2 nM
(Figure 3b), again in reasonable agreement with previous reports
[26,27], although surprisingly we failed to observe a rightward
shift in the potency of BNP relative to ANP. This may reflect the
fact that we were comparing mouse BNP-45 provided by one
manufacturer to rat ANP-28 provided by a different manu-
facturer. As with ANP, lung membranes from Npr1−/− animals
are essentially insensitive to BNP. When tested with CNP,
membranes from Npr1+/+ lung clearly show both high and low
affinity responses (Figure 3c). The EC
&!
of the high affinity
component is approx. 0.6 nM, consistent with an NPRB-
mediated response [27,38], whereas the EC
&!
for the low affinity
component is well above 100 nM. It is likely that the low
affinity response is a consequence of cross-activation of NPRA
by CNP, since this component is absent in membranes obtained
from the Npr1−/− animals (Figure 3c). This idea is compatible
with the known low affinity of recombinant NPRA for CNP [27].
These results give rise to several interesting observations. First,
the lack of effect of ANP and BNP in Npr1−/− membranes
indicates that the mutation is not ‘ leaky’, and that NPRA is the
only rGC that mediates responses to both of these peptides in
lung. Most importantly, ANP and BNP do not significantly
cross-activate NPRB, which is clearly present in Npr1−/− lung
membranes. Second, the maximal activity of NPRB in lung is
much less than the maximal activity of NPRA. Third, the activity
of NPRB has not been significantly up- or down-regulated in
Npr1−/− animals, indicating a lack of compensatory regulation
following the ablation of NPRA. This can be seen by focusing on
the appropriate portions of the concentration–response curves in
Figure 3c (over the range of 0–10 nM ligand), where it is
apparent, despite some scatter, that the magnitudes of the high
affinity CNP responses are quite similar in both Npr1+/+ and
Npr1−/− animals.
Tissue survey of ANP-dependent rGC activity
Although the results in Figure 3 demonstrate that NPRA is the
only rGC in lung that responds to ANP or BNP, it is possible
that alternative rGCs might be expressed in other tissues. Figure
4 shows basal and stimulated rates of membrane cyclase activity
in a number of Npr1+/+ and Npr1−/− tissues tested with a
saturating dose of ANP. In Npr1+/+ animals, adrenal gland,
kidney, lung and testis show the greatest responses to ANP,
while liver and brain display small responses. Heart and colon
respond only marginally. Surprisingly, thoracic aorta has no
detectable cyclase activity, even in the presence of ANP, although
the amount of protein included in the assay was comparable to
that tested for other tissues.
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Figure 4 Tissue distribution of ANP-stimulated GC activity
Initial rates of cGMP synthesis were determined for plasma membranes isolated from organs
of Npr1+/+ mice (upper panel), or Npr1−/− mice (lower panel) in the presence (­) or
absence (®) of a saturating dose of ANP (mean³S.E.M. for responses to 1 µM agonist). Note
the difference in scales between the upper and lower panels. The numbers in parentheses
denote the number of independent animals tested. *, P ! 0.05 relative to control ; **, P ! 0.01 ;
***, P ! 0.001.
In contrast, Npr1−/− tissues are almost completely un-
responsive to ANP (although, as described below, small residual
responses are observed in adrenal gland). This argues that, in the
tissues surveyed, ANP at 10 µM does not significantly activate
any rGC other than NPRA. Therefore, the magnitudes of the
responses to ANP observed in Npr1+/+ tissues should provide
an accurate index of NPRA expression. Indeed, the distribution
of the biochemical responses correlates well with the distri-
bution of NPRA immunoreactivity, shown in Figure 1(b),
though the enzyme assay is obviously more sensitive than
Western blotting.
NPRA is the dominant GC receptor for BNP
We next measured cGMP synthesis by membranes isolated from
various wild-type tissues under control conditions or in response
to a saturating concentration of BNP (Figure 5, upper panel).
Adrenal gland, kidney, lung and testis exhibit robust responses,
liver displays a small response, heart, brain and colon respond
marginally, if at all, and activity is again undetectable in aorta.
The pattern of sensitivity to BNP is similar to the pattern
established for ANP (Figure 4, upper panel), and there is good
agreement when the relative magnitudes of the BNP responses
(stimulated rate minus basal rate) are compared to the relative
magnitudes of the ANP responses determined in the same tissue
(Figure 5, lower panel). These results indicate that NPRA is the
dominant rGC responsible for BNP-activated cGMP synthesis,
at least when high concentrations of BNP are applied.
We then examined responses to BNP in Npr1−/− mice, where
the elimination of NPRA makes it easier to detect the activity of
Figure 5 Tissue distribution of BNP-stimulated GC activity
Initial rates of cGMP synthesis were determined for plasma membranes isolated from organs
of Npr1+/+ mice (upper panel), or Npr1−/− mice (middle panel) in the presence (­) or
absence (®) of a saturating dose of BNP (mean³S.E.M. for pooled responses to 0.1 and
1 µM of agonist). Note the difference in scales between the upper and middle panels. The
numbers in parentheses denote the number of independent animals tested. *, P ! 0.05 relative
to control ; **, P ! 0.01 ; ***, P ! 0.001. The bottom panel shows each NPRA+/+ tissue’s
average net BNP response (black bars) plotted adjacent to that same tissue’s average net ANP
response (grey bars). The net response is determined for each sample of membranes tested
by subtracting its basal rate from its stimulated rate.
any additional BNP-sensitive GC (Figure 5, middle panel). The
effects of the peptide are markedly attenuated in all tissues, again
confirming that NPRA is the most abundant rGC capable of
synthesizing cGMP in response to BNP. However, as with ANP,
small but statistically significant responses are retained by some
of the Npr1−/− tissues, most prominently testis and adrenal gland.
Indeed, in Npr1−/− animals the effects of BNP on these two
tissues are noticeably greater than those provoked by ANP, and
amount to about 10% of the BNP responses measured in the
corresponding Npr1+/+ tissues (Figure 6).
Residual BNP responses in Npr1−/− animals are not mediated by
NPRB
At high concentrations, both ANP and BNP can activate the GC
activity of rat NPRB [26,27,38]. Thus, if particularly high levels
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Figure 6 Time courses of basal and agonist-activated cGMP synthesis
carried out by membranes from Npr1−/− and Npr1+/+ testis and adrenal
gland
Each panel shows the effects of ANP and BNP on the initial rate of cGMP synthesis by Npr1−/−
membranes (left panels) or Npr1+/+ membranes (right panels), analysed over a 10 min time
course. The points report the mean³S.E.M. at each time point for membranes stimulated with
1 µM ANP or 1 µM BNP, and their respective paired controls. The numbers in parentheses
denote the numbers of animals tested with each ligand. Note the differences in scale between
the Npr1−/− and Npr1+/+ tissues. *, P ! 0.05 relative to control.
of NPRB were to be expressed in Npr1−/− testis and adrenal
gland, then they could account for the residual responses to BNP
and ANP. NPRB levels can be quantitated in an Npr1−/− tissue
by measuring the tissue’s response to a saturating dose of CNP,
since we have shown that CNP becomes a selective NPRB
agonist in the absence of NPRA (Figure 3c). Figure 7 (upper
panel) shows that testis and adrenal gland do not express
unusually high levels of NPRB relative to other tissues. Fur-
thermore, the tissue distribution of the net responses (stimulated
rate minus basal rate) elicited by CNP in Npr1−/− animals is
distinct from the distribution of the net responses elicited by
BNP (Figure 7, lower panel). For example, both Npr1−/− colon
and lung respond robustly to CNP, but are completely insensitive
to BNP, whereas Npr1−/− testis and adrenal gland provide the
largest responses to BNP and are only moderately sensitive to
CNP. This demonstrates that BNP and CNP cannot both be
acting through the same receptor (i.e. NPRB), since if they were,
the ratio of the two responses should remain constant in every
tissue.
To further investigate the residual responses present in
Npr1−/− testis, we evaluated the effects of a full range of agonist
concentrations (Figure 8). The threshold for the BNP response is
in the vicinity of 1 nM, while the threshold for the ANP response
is approx. 100-fold higher. We obtained a good fit to the BNP
results by using a single-site model with an EC
&!
of 20 nM,
Figure 7 Tissue distribution of CNP-stimulated GC activity in Npr1−/−
mice
The upper panel shows initial rates of cGMP synthesis determined for plasma membranes
isolated from organs of Npr1−/− mice in the presence (­) or absence (®) of a saturating
dose of CNP (mean³S.E.M. for pooled responses to 0.1 and 1 µM of agonist). The number
in parentheses denotes the number of independent animals tested. *, P ! 0.05 relative to
control ; **, P ! 0.01 ; ***, P ! 0.001. The lower panel compares each mutant tissue’s net
CNP response (stimulated rate minus basal rate, grey bars) to that same tissue’s net response
to 0.1 µM BNP (stimulated rate minus basal rate, filled bars).
Figure 8 Testis membranes from Npr1−/− animals respond to BNP with
high affinity
Analysis of the effects of ANP (D) or BNP (E) on cGMP synthesis by testis membranes
(stimulated rate/basal rate). Each point gives the mean³S.E.M. (n ¯ 7 for BNP and n ¯
5 for ANP). The curves were calculated using a single-binding-site equation, as described in
the Experimental section. Values for Vmax (BNP, 2.2 ; ANP, 2.2) and EC50 (BNP, 2 nM; ANP,
1 µM) were adjusted by eye to provide an optimal fit.
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Figure 9 Basal GC activity varies from tissue-to-tissue, and reflects
variable contributions of NPRA
Initial basal rates of cGMP synthesis were determined for plasma membranes isolated from
organs of Npr1+/+ mice or Npr1−/− mice. Each bar gives the mean³S.E.M. The number
in parentheses denotes the number of independent pairs of animals tested. *, P ! 0.05 relative
to wild-type ; **, P ! 0.01 ; ***, P ! 0.001.
though the results do not allow us to definitively rule out a
multiple-site model. Nevertheless, these results again argue
strongly that the BNP responses are not mediated by NPRB.
First, the EC
&!
for BNP activation of recombinant rodent
NPRB [26,27,38] is nearly two orders of magnitude higher than
the EC
&!
for the BNP responses that we observe in Npr1−/− testis.
Second, recombinant NPRB is approximately equally responsive
to ANP and BNP [26,27,38], whereas the receptor that mediates
the high affinity BNP responses in Npr1−/− testis is clearly quite
insensitive to ANP.
Taken together, the results in Figures 4–8 support two principal
conclusions : (1) NPRA is the most abundant rGC capable of
generating cGMP-dependent responses to BNP, and (2) certain
tissues display an additional, less prominent BNP-selective
activity that is mediated by a high affinity mechanism distinct
from both NPRA and NPRB.
The basal rate of cGMP synthesis reflects the complement of
membrane GCs expressed by each tissue
A low rate of activity in the absence of ligand is characteristic of
many receptors, including rGCs. As can be shown in Figures
4–6, the basal rate of cyclase activity observed in tissues derived
from Npr1−/− animals is often much lower than that observed
in corresponding tissues from Npr1+/+ animals (note the dif-
ferences in scale). We have pooled together all of the measure-
ments that were made in the course of our studies, and have used
these results to determine the basal cyclase activity for each
Npr1+/+ and Npr1−/− tissue (Figure 9). In some tissues (for
example, lung, forebrain and liver) the basal rate at which cGMP
is synthesized by Npr1−/− and Npr1+/+ membranes is not
statistically different, implying only a minor contribution to
basal activity by NPRA. In contrast, adrenal gland, kidney and
testis show a large proportional decrease of basal activity in
mutant membranes relative to wild-type membranes, consistent
with a dominant role for NPRA in controlling cGMP metabolism
in these tissues. Furthermore, the amount of basal cyclase activity
remaining in each Npr1−/−tissue reveals the extent to which
membrane cyclases other than NPRA are active in that tissue.
The rank order for residual basal cyclase activity (pmol of
cGMP synthesized}min per mg of protein) in tissues from
Npr1−/− animals is as follows: lung, 6.1³1.3 (n¯ 25) ; colon,
4.0³0.6 (n¯ 18) ; adrenal gland, 2.4³0.6 (n¯ 9) ; forebrain,
1.5³0.3 (n¯ 8) ; kidney, 1.0³0.1 (n¯ 23) ; testis, 0.9³0.1
(n¯ 12) ; heart, 0.6³0.2 (n¯ 8) ; liver, 0.5³0.1 (n¯ 11) ;
aorta, 0 (n¯ 2).
At least part of the basal activity remaining in many tissues
must reflect the contribution of NPRB. Based on responsiveness
to CNP (Figure 7), NPRB is expressed prominently in adrenal
gland, lung, kidney, testis, liver, colon and heart. In contrast,
CNP has relatively little effect on membranes isolated from
forebrain. Interestingly, in wild-type forebrain membranes there
is also only a small increase in cGMP after stimulation with ANP
or BNP (Figures 4 and 5), and 97% of the relatively high basal
GC activity remains after NPRA deletion (Figure 9). This
suggests that membrane-associated GCs other than NPRA and
NPRB are prevalent in this tissue. Since neither the residual
response to BNP nor any of the other currently identified
members of the rGC family are prominently expressed in
forebrain, it seems likely that novel rGCs (or perhaps other, as
yet uncharacterized, GC isoforms that are not in the rGC family)
remain to be discovered in the nervous system.
DISCUSSION
Although it is well accepted that ANP and BNP, acting through
NPRA, play important roles in blood pressure and fluid volume
homoeostasis [1–9,31], significant gaps remain in our under-
standing of this critical endocrine pathway. For example, we lack
a systematic ‘ functional ’ evaluation of NPRA activity across a
representative spectrum of tissues. Such measurements are of
significant interest, given the known dependency of NPRA
activity on phosphorylation state [36]. A related issue, important
for understanding how NP signalling pathways influence blood
pressure in the intact animal, is whether the activity of NPRB, a
structurally similar rGC, can be up-regulated (through phos-
phorylation or some other mechanism) to compensate for
deficiencies in NPRA signalling. An additional long-standing,
unanswered question is whether BNP (which activates NPRA
with significantly lower potency than does ANP) might actually
serve as the preferred agonist at some alternative, yet-to-be-
identified receptor. Gene targeting has been used to disrupt the
murine gene encoding NPRA [7,31], providing an optimal
experimental system in which to address these issues.
The most novel finding of the present study is the observation
that certain tissues from NPRA-deficient animals (notably testis
and adrenal gland) retain a significant level of responsiveness to
BNP, though they have lost the ability to respond to physio-
logically relevant levels of ANP. This strongly implies the
existence of a BNP-preferring receptor that is preferentially
expressed in steroid-producing tissues. The cGMP-producing
capacity of this BNP-preferring pathway is low (approx. 10% of
the capacity of the NPRA pathway), suggesting either that we
have not yet identified the ligand that activates it most effectively,
or that its signalling function may be carried out only within a
subset of cells in each responsive tissue.
A number of observations suggest that these residual responses
are not mediated by any of the currently-known rGCs. (1) They
cannot be mediated by NPRA, since the NPRA gene has been
ablated in the mutant animals, and we find no evidence that this
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mutation is ‘ leaky’. (2) Although NPRB responds weakly to
both ANP and BNP, its EC
&!
for activation by BNP is greater
than 1 µM [26,27,38], at least two orders of magnitude higher
than the EC
&!
of the residual BNP responses mediated by the
putative BNP receptor. Furthermore, we find an obvious mis-
match between the ability of mutant tissues to respond to CNP
(the most potent known ligand for NPRB) and BNP, implying
that the two peptides are acting through distinct receptors. (3)
None of the other known mammalian rGCs are significantly
sensitive to ANP or BNP, although one of them (GC-G) does
respond very weakly to ANP [39]. GC-G is, however, completely
insensitive to BNP, and its tissue distribution in rats (high in
lung, and undetectable in testis and adrenal gland) is inconsistent
with the tissue distribution of the residual BNP responses that we
observe in Npr1−/− mice.
We know little about the receptor that mediates the residual
BNP responses, other than that it can enhance net cGMP
synthesis, and that it prefers BNP over ANP. If this receptor is
a member of the rGC family, its low abundance may provide an
explanation for why it has not been cloned from any of the
cDNA libraries used in previous studies. Alternatively, it could
represent a novel type of membrane GC that has not been
identified in standard library screens because it lacks sufficient
structural homology to the rGC family. As an additional
possibility, it may be that the properties of a known rGC, such
as NPRB, have been altered in specific tissues (for example, by
post-translational modification or by association with an ac-
cessory subunit), so that the modified receptor has become
capable of mediating the responses that we observe. Finally, the
receptor could be coupled in an inhibitory way to a phospho-
diesterase that breaks down cGMP. If so, the targeted phos-
phodiesterase must be membrane-associated and resistant to
IBMX, a broad-spectrum phosphodiesterase inhibitor that is
routinely included in our incubation mixture.
If a BNP-preferring signalling pathway does indeed exist, then
it is likely to be affiliated with physiological responses distinct
from those that are regulated by NPRA. In this regard, it is
worth noting that the phenotypes of ANP and BNP knockout
animals are not equivalent. ANP knockout animals develop
hypertension and cardiac hypertrophy, without reported signs of
cardiac fibrosis [40], whereas BNP knockout animals frequently
develop fibrotic lesions throughout their ventricles, but have
normal blood pressures, normal sized hearts and normal cir-
culating levels of ANP [41]. This strongly suggests that there are
aspects of BNP signalling that cannot be substituted by ANP
acting through NPRA, and provides indirect support for the
existence of a BNP-preferring receptor. If the role of this receptor
is to suppress cardiac fibrosis (as implied by the phenotype of the
BNP deficient animals), then the BNP-selective responses that we
have observed in steroid-producing tissues are of particular
interest, given the well known relationship between steroids and
fibrosis [42]. Together, these observations suggest that one unique
function of BNP may be to limit fibrosis by controlling steroid
production.
A second goal of our studies was to determine if rGC activity
is maintained in proportion to protein levels, or whether feedback
mechanisms might alter enzyme activity to keep it at, or near, a
biological optimum in specific tissues, or in response to changes
in blood pressure. Our functional studies show that the tissue
distribution of NPRA-mediated cGMP synthesis agrees well
overall with the distribution of immunoreactive NPRA. By both
measures, expression is high in adrenal gland, kidney and lung,
and lower, but still abundant in testis and liver. This expression
pattern is substantiated by a spectrum of well established
physiological actions of ANP in kidney [6,31,43], adrenal gland
[44], lung [45], testis [46] and liver [47–49]. The correlation that
we observe between NPRA protein levels and NPRA-mediated
enzyme activity indicates that, under normal circumstances,
regulatory mechanisms (such as protein phosphorylation) do not
significantly adjust the function of NPRA in specific tissues.
Somewhat surprisingly, this also appears to be the case under
hypo- or hypertensive conditions. In a previous study [9], we
used mice with 1, 2, 3 and 4 copies of the gene encoding NPRA
to evaluate the relationship between gene-copy number, blood
pressure and NPRA-dependent enzyme activity. Despite the fact
that the genetically modified animals show significant differences
in blood pressure, they maintain a strikingly linear relationship
between NPRA gene-copy number and ANP-stimulated cGMP
synthesis. As an alternative, a mouse with altered NPRA
expression could also normalize its blood pressure through
compensatory changes in NPRB activity. However, our current
measurements indicate that there is no difference in NPRB rGC
activity in the lungs of Npr1−/− mice relative to Npr1+/+ mice,
despite the fact that this tissue is highly vascularized. Taken
together, these results suggest that neither protein expression
levels nor enzyme activity of peptide-sensitive rGCs is altered to
compensate for chronic deviations in blood pressure.
In summary, our studies provide evidence that BNP can alter
cGMP levels in mouse tissues by at least two different high
affinity mechanisms. One mechanism employs NPRA, a con-
ventional high-capacity rGC that is particularly abundant in
adrenal gland, lung, kidney, testis and liver. The second mech-
anism activates an as yet unspecified lower-capacity response
that can be observed only in adrenal gland and testis. Although
the physiological significance and biochemical components of
this second mechanism remain to be established, its existence
does reinforce the notion that, consistent with their independent
structures, ANP and BNP are likely to carry out at least some
independent actions. In addition, our results indicate that, unlike
many other receptors that play a role in blood pressure homoeo-
stasis, the activity and expression levels of the rGCs are not
tightly regulated by feedback mechanisms. This leads to the
prediction that any mutation leading to loss or gain of NPRA or
NPRB function should alter the cellular response to the NPs in
direct proportion to the activity of the mutant gene product,
reinforcing the notion that polymorphisms in the genes encoding
the rGCs may contribute to the genetic basis of hypertension [9].
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